Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis

Qiao, Jian-Bin; Fan, Qianqian; Liu, Xing; Cui, Pengfei; He, Yujing; Zhu, Jing-Cheng; Wang, Lirui; Pang, Tao; Oh, Yu‐Kyoung; Zhang, Chaofeng; Jiang, Hu‐Lin

doi:10.1016/j.jconrel.2018.05.032

Cited by 78 publications

(45 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Down regulation of Pdgfrb expression caused suppression of activated HSCs and improvement of liver function 97 . The effectiveness of siRNAs among the various gene therapies has been revealed by different researcher and the prominent studies are summarized in Table 3 76 , 80 , 91 , 93 , 96 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 .…”

Section: Gene Deliverymentioning

confidence: 99%

Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives

Mahdinloo

Kiaie

Amiri

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Liver fibrosis results from chronic damages together with an accumulation of extracellular matrix, and no specific medical therapy is approved for that until now. Due to liver metabolic capacity for drugs, the fragility of drugs, and the presence of insurmountable physiological obstacles in the way of targeting, the development of efficient drug delivery systems for anti-fibrotics seems vital. We have explored articles with a different perspective on liver fibrosis over the two decades, then collected and summarized the information by providing corresponding in vitro and in vivo cases. We have discussed the mechanism of hepatic fibrogenesis with different ways of fibrosis induction in animals. Furthermore, the critical chemical and herbal anti-fibrotics, biological molecules such as micro-RNAs, siRNAs, and growth factors, which can affect cell division and differentiation, are mentioned. Likewise, drug and gene delivery and therapeutic systems on in vitro and in vivo models are summarized in the data tables. This review article enlightens recent advances in emerging drugs and nanocarriers and represents perspectives on targeting strategies employed in liver fibrosis treatment.

show abstract

Section: Gene Deliverymentioning

confidence: 99%

Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives

Mahdinloo

Kiaie

Amiri

et al. 2020

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…CRM/NIL loaded with nilotinib (NIL), a second-generation tyrosine kinase inhibitor used for the treatment of liver fibrosis, showed excellent antifibrotic efficiency ( Figure 4 ). In addition, polymeric micelles (PVMs) formed with PLGA-polyspermine-PEG-VA were used to target HSCs and deliver the chemical drug silibinin and genetic drug siCol1α1 to the liver fibrosis site [ 101 ]. The double-loaded polymer micelle more efficiently reduced collagen I and ameliorated liver fibrosis, compared with the PVMS loaded with either the chemical drug only or genetic drug only.…”

Section: Nanomedicine For Liver Fibrosis Therapymentioning

confidence: 99%

Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis

Bai

Zhai

2020

Nanomaterials

View full text Add to dashboard Cite

Liver fibrosis, a reversible pathological process of inflammation and fiber deposition caused by chronic liver injury and can cause severe health complications, including liver failure, liver cirrhosis, and liver cancer. Traditional diagnostic methods and drug-based therapy have several limitations, such as lack of precision and inadequate therapeutic efficiency. As a medical application of nanotechnology, nanomedicine exhibits great potential for liver fibrosis diagnosis and therapy. Nanomedicine enhances imaging contrast and improves tissue penetration and cellular internalization; it simultaneously achieves targeted drug delivery, combined therapy, as well as diagnosis and therapy (i.e., theranostics). In this review, recent designs and development efforts of nanomedicine systems for the diagnosis, therapy, and theranostics of liver fibrosis are introduced. Relative to traditional methods, these nanomedicine systems generally demonstrate significant improvement in liver fibrosis treatment. Perspectives and challenges related to these nanomedicine systems translated from laboratory to clinical use are also discussed.

show abstract

“…The mannose-6-phosphate/insulin-like growth factor II (IGFII) receptor was the first receptor studied for this purpose [29], followed by the collagen type VI receptor [30], and the PDGF-β-receptor [17,31]. A monoclonal antibody against the synaptophysin receptor also has been tested, but without follow-up [32], and in the recent years, many studies have been published using the vitamin A receptor upon HSC as target receptor for antifibrotic compounds [33][34][35][36][37]. A lipid nanoparticle functionalized with vitamin A and containing siRNA against heat shock protein 47 (HSP47) is now being tested in clinical phase 2 trials (www.…”

Section: Uptake Of Drugs and Nanomedicines In The Livermentioning

confidence: 99%

Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell

Poelstra

2020

Curr. Tissue Microenviron. Rep.

View full text Add to dashboard Cite

Purpose of Review Treatment of liver fibrosis benefits from hepatic stellate cell (HSC)-specific delivery. Since the description of first carrier to HSC, many developments have taken place in this area. The purpose is to give an overview of the different carriers and homing moieties that are available for HSC targeting and illustrate the opportunities and hurdles they provide. Recent Findings There is a growing number of homing devices to deliver drugs to HSC, and options to deliver siRNA to HSC have emerged. Other developments include controlling corona formation, development of linker technology, and design of theranostic approaches. We are on the eve of reaching the clinic with innovative HSC-specific compounds. Summary An overview of different core molecules is presented together with an overview of targeting strategies toward different receptors on HSC, providing a versatile toolbox. Many therapeutics, ranging from small chemical entities and proteins to RNAor DNA-modulating substances, have already been incorporated in these constructs in the recent years.

show abstract

Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis

Cited by 78 publications

References 38 publications

Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives

Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives

Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis

Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell

Contact Info

Product

Resources

About